Pope W B, Lai A, Nghiemphu P, Mischel P, Cloughesy T F
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Neurology. 2006 Apr 25;66(8):1258-60. doi: 10.1212/01.wnl.0000208958.29600.87.
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
复发性胶质瘤患者（n = 14）接受了贝伐单抗与卡铂、伊立替康或依托泊苷联合治疗。在开始治疗后2至6周进行了随访磁共振成像扫描。7例患者的强化肿瘤缩小，在开始治疗后短短2周就有明显缩小。与实性强化肿瘤相比，治疗对异质性强化肿瘤似乎更有效。
